|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
One hundred microRNA precursors were aberrantly expressed in pancreatic cancer or desmoplasia (p < 0.01), including microRNAs previously reported as differentially expressed in other human cancers (miR-155, miR-21, miR-221 and miR-222) as well as those not previously reported in cancer (miR-376a and miR-301).
|
17149698 |
2007 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
One hundred microRNA precursors were aberrantly expressed in pancreatic cancer or desmoplasia (p < 0.01), including microRNAs previously reported as differentially expressed in other human cancers (miR-155, miR-21, miR-221 and miR-222) as well as those not previously reported in cancer (miR-376a and miR-301).
|
17149698 |
2007 |
|
Pancreatic carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
One hundred microRNA precursors were aberrantly expressed in pancreatic cancer or desmoplasia (p < 0.01), including microRNAs previously reported as differentially expressed in other human cancers (miR-155, miR-21, miR-221 and miR-222) as well as those not previously reported in cancer (miR-376a and miR-301).
|
17149698 |
2007 |
|
Malignant neoplasm of pancreas
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
One hundred microRNA precursors were aberrantly expressed in pancreatic cancer or desmoplasia (p < 0.01), including microRNAs previously reported as differentially expressed in other human cancers (miR-155, miR-21, miR-221 and miR-222) as well as those not previously reported in cancer (miR-376a and miR-301).
|
17149698 |
2007 |
|
Prostate carcinoma
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1.
|
17569667 |
2007 |
|
Carcinoma
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Here we show that miR-221 and miR-222, encoded in tandem on chromosome X, are overexpressed in the PC3 cellular model of aggressive prostate carcinoma, as compared with LNCaP and 22Rv1 cell line models of slowly growing carcinomas.
|
17569667 |
2007 |
|
Glioblastoma
|
0.100 |
Biomarker
|
disease |
LHGDN |
Regulation of p27Kip1 by miRNA 221/222 in glioblastoma.
|
17721077 |
2007 |
|
Papillary thyroid carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Consistent with these results, an enforced expression of the miR-221 and miR-222 induced the thyroid papillary carcinoma cell line (TPC-1) to progress to the S phase of the cell cycle.
|
17914108 |
2007 |
|
Thyroid carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Here, we report that the enforced expression of miR-221 and miR-222 was able to reduce p27(Kip1) protein levels in thyroid carcinoma and HeLa cells in the absence of significant changes in specific p27(Kip1) mRNA levels.
|
17914108 |
2007 |
|
Carcinoma, Papillary
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
It is likely that the negative regulation of p27(Kip1) by miR-221 and miR-222 might also have a role in vivo since we report an inverse correlation between miR-221 and miR-222 up-regulation and down-regulation of the p27(Kip1) protein levels in human thyroid papillary carcinomas.
|
17914108 |
2007 |
|
Leukemia, Myelocytic, Acute
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
In contrast, the MIRN221/MIRN222 cluster and MIRN34A were expressed at significantly higher levels in AML blasts.
|
18173753 |
2008 |
|
melanoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Specifically, PLZF silencing in melanomas unblocks miR-221 and miR-222, which in turn controls the progression of the neoplasia through down-modulation of p27Kip1/CDKN1B and c-KIT receptor, leading to enhanced proliferation and differentiation blockade of the melanoma cells, respectively.
|
18417445 |
2008 |
|
Acute Promyelocytic Leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We have identified the promyelocytic leukemia zinc finger (PLZF) transcription factor as a repressor of miR-221 and miR-222 by direct binding to their putative regulatory region.
|
18417445 |
2008 |
|
Promyelocytic leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We have identified the promyelocytic leukemia zinc finger (PLZF) transcription factor as a repressor of miR-221 and miR-222 by direct binding to their putative regulatory region.
|
18417445 |
2008 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our study identified and validated miR-224 overexpression in all tumors and miR-200c, miR-200, miR-21, miR-224, miR-10b, and miR-222 specific deregulation in benign or malignant tumors.
|
18433021 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Specific microRNA (miR)-223 and miR-222 deregulations were verified in an independent series of tumors.
|
18555017 |
2008 |
|
Liver carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
Further investigations suggested the highly deregulated miR-223 and miR-222 could unequivocally distinguish HCC from adjacent nontumoral liver, irrespective of viral associations (P <or= .0002).
|
18555017 |
2008 |
|
Carcinoma, Papillary
|
0.030 |
Biomarker
|
disease |
BEFREE |
When applied to 40 FNA samples of various lesions, only miR-146b and miR-222 persisted as distinguishing markers for papillary carcinoma.
|
18587330 |
2008 |
|
Mammary Neoplasms
|
0.320 |
Biomarker
|
group |
LHGDN |
MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1.
|
18708351 |
2008 |
|
Malignant neoplasm of breast
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These findings indicate that miR-221 and miR-222 play a significant role in the regulation of ERalpha expression at the protein level and could be potential targets for restoring ERalpha expression and responding to antiestrogen therapy in a subset of breast cancers.
|
18790736 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MiR-221 and miR-222 are two highly homologous microRNAs whose upregulation has been recently described in several types of human tumors, for some of which their oncogenic role was explained by the discovery of their target p27, a key cell cycle regulator.
|
19107213 |
2008 |
|
Prostate carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice.
|
19107213 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MiRNAs showing high expression in muscle invasive tumors included miR-222 and miR-125b and in Ta tumors miR-10a.
|
19127597 |
2009 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Ectopic expression of miR-222 cluster enhanced tumor growth in the mouse xenograft model.
|
19153141 |
2009 |
|
Lung Neoplasms
|
0.310 |
Biomarker
|
group |
BEFREE |
In order to investigate whether there are similar patterns of miRNA expression levels in pseudoglandular human embryonic lung and in human lung tumors, we have analyzed 18 miRNAs (the let-7 family, the miR-17-92 cluster, miR-221 and miR-222) in human embryonic lung samples and in paired lung tumor and normal lung tissue samples and correlated the results with clinicopathological characteristics.
|
19209007 |
2009 |